Drugs / GT-UGT1A1-AAV8-02
GT-UGT1A1-AAV8-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06641154 | Nov 2024 → Nov 2027 expected | Crigler-Najjar syndrome type 1 | Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT-UGT1A1-AAV8-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641154 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “GT-UGT1A1-AAV8-02 (alphaglucuronosyltransferasegene unoparvovec, alphacrigen, OGP-001, AAV-TBG1A1) is comprised of a recombinant adeno-associated virus type 2/8 (rAAV2/8)” NCT06641154 ↗ |
| Route | Intravenous | “Intravenous infusion, single dose” NCT06641154 ↗ |
| Target | UGT1A1 | “carrying the normal human UGT1A1 gene” NCT06641154 ↗ |